Single daily dose administration of cyclosporine in renal transplant recipients
| Autor: | P. Nair, T. Al-Otaibi, A.E. Gawish, M.R.N. Nampoory, M.A. Halim, I. Al-Muzairai, T. Said, S. Eleawa, M. Al-Mousawi, H. Al-Maged |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male medicine.medical_specialty Urinary system Urology Drug Administration Schedule medicine Humans Dosing Adverse effect Aged Retrospective Studies Hepatitis Transplantation Kidney business.industry Histocompatibility Testing Retrospective cohort study Middle Aged medicine.disease Ciclosporin Kidney Transplantation Surgery medicine.anatomical_structure Treatment Outcome Cyclosporine Female business Immunosuppressive Agents medicine.drug Follow-Up Studies |
| Zdroj: | Transplantation proceedings. 39(4) |
| ISSN: | 0041-1345 |
| Popis: | Cyclosporine (CsA) microemulsion has been the mainstay immunosuppressive agent for renal transplant recipients for years. A single daily dosing of cyclosporine (SD) is rarely used. The objective of this study was to evaluate the efficacy of SD versus twice daily dosing of CsA. Retrospective evaluation of SD use was conducted for 44 renal transplant recipients for 12 months (study group). Equal numbers of matched recipients were selected for age, sex, HLA mismatch, donor type, and immunosuppressive regimen (control group). We measured CsA trough (C0) and peak (C2) blood levels, 12-hour CsA profile, and the area under the concentration-time curve (AUC). There were significant differences in C0, C2, and calculated AUC after shifting to SD. In the study group, the mean AUC was 4619 ng/mL/h before versus 6567 ng/mL/h after shifting to SD (P=.004). This became more therapeutic and identical to the mean AUC in the control group, which was 6551 ng/mL/h. Total daily CsA dose was significantly lower in the study group compared with the control group (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect